Form 4: Vigil Neuroscience CEO Receives Repriced Stock Options

Ivana Magovcevic-Liebisch, President and CEO of Vigil Neuroscience, received repriced stock options on May 3, 2024, under the company's 2021 Stock Option and Incentive Plan.

Summary

• On May 3, 2024, Vigil Neuroscience's Board of Directors approved a stock option award repricing for Ivana Magovcevic-Liebisch, the company's President and CEO.
• The repricing affects two stock option awards, one for 282,000 shares and another for 370,000 shares.
• The exercise price for both awards was adjusted to $3.03 per share, reflecting the fair market value of Vigil Neuroscience's common stock on the effective date.
• The original exercise prices for the 282,000 and 370,000 share awards were $16.13 and $11.87 respectively.
• The options vest in equal monthly installments over 48 months, with the original vesting start dates being April 1, 2022, and April 1, 2023, respectively.
• The repriced options will revert to their original exercise price if exercised during a one-year Retention Period, or upon a Sale Event, termination of service (other than for cause or due to death/disability), or termination for Good Reason.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the repricing is a positive incentive for the CEO, it also reflects potential past underperformance of the stock. The retention period adds a layer of complexity but is generally a standard practice.

Positives

• The repricing of stock options may incentivize the CEO to improve company performance and increase shareholder value.
• The Retention Period provides a mechanism to ensure the CEO remains committed to the company's long-term success.

Negatives

• The repricing suggests the stock price may have underperformed, leading to the need to adjust the option terms to maintain their incentive value.
• The Retention Period adds complexity to the option terms and could potentially disincentivize the CEO if the conditions for reversion are perceived as overly restrictive.

Risks

• The repricing could be viewed negatively by shareholders if it is perceived as rewarding underperformance.
• The Retention Period could create uncertainty and potentially lead to disputes if the conditions for reversion are not clearly defined or are subject to interpretation.

Future Outlook

The document does not contain any specific forward-looking statements or guidance beyond the terms of the stock option awards.

Industry Context

Repricing stock options is a common practice in the biotechnology industry when a company's stock price has declined significantly. It is used to re-incentivize key executives and retain talent. This is similar to actions taken by other biotech companies facing stock price challenges.

Comparison to Industry Standards

• Stock option repricing is a relatively common practice, especially in volatile sectors like biotechnology.
• Companies like BioMarin Pharmaceutical and Amgen have also repriced options in the past to maintain executive incentives.
• The vesting schedules and retention periods are fairly standard compared to industry norms for executive compensation packages.

Stakeholder Impact

• Shareholders may view the repricing as a positive step to incentivize management, or negatively if they believe it rewards underperformance.
• Employees may see the repricing as a sign of the company's commitment to its leadership.

Key Dates